JPRN-UMIN000016265已完成未知
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myeloma - HCHSG-MM-214
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Non-secretory multiple myeloma or plasma cell leukemia. HIV-, HBs-, or HCV-positive patients. Severe or uncontrolled hepatic dysfunction, renal failure, cardiac dysfunction, pulmonary dysfunction, diabetes, hypertension, infection, or psychiatric disorder. Patients with active and progressive malignancy. Women who are pregnant or in lactation. Those who are considered as inappropriate to register by attending physicians.
研究者
相似试验
已完成
2 期
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39
进行中（未招募）
1 期
A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes - GFM- Aza-Ida-09Myelodysplastic syndromesMedDRA version: 12.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-017178-19-FRGroupe Francophone des Myélodysplasies56
招募中
2 期
uPBSCT with PTCY for ATadult T-cell leukemia/lymphomaJPRN-jRCTs031200375Fukuda Takahiro24
招募中
不适用
Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomasJPRN-UMIN000011152B-SRIM Study Group38
进行中（未招募）
1 期
Study to evaluate efficacy and safety of sunitinib in patients with renal cell carcinoma who have progressed to first-line immunotherapy treatmentmetastatic renal clear cell carcinomaMedDRA version: 19.1Level: LLTClassification code 10038416Term: Renal clear cell carcinomaSystem Organ Class: 100000004864EUCTR2016-004011-12-ESSOGUG (Spanish Oncology Genitourinary Group)